New drug combo offers hope for myelofibrosis patients who failed standard therapy

NCT ID NCT05393674

Completed Disease control Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, fedratinib and nivolumab, in 30 adults with myelofibrosis whose disease no longer responded well to standard JAK-inhibitor treatment. The goal was to see if the combination could shrink the spleen, improve symptoms, or reduce the need for blood transfusions. The study is now complete, and results will help determine if this approach is safe and effective enough for further testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY MYELOFIBROSIS SECONDARY MYELOFIBROSIS

Contacts and locations

Locations

Johannes Wesling Klinikum

Minden, Germany
Medizinische Hochschule

Hanover, Germany
Uniklinik Ulm

Ulm, Germany
University Medicine Greifswald

Greifswald, Germany
Universitätsklinikum Freiburg

Freiburg im Breisgau, Germany
Universitätsklinikum Halle (Saale)

Halle, Germany
Universitätsklinikum Schleswig-Holstein

Lübeck, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.